AsianScientist (Jul. 13, 2016) – CStone Pharmaceuticals, a Chinese biopharmaceutical company whose core therapeutic focus is in immuno-oncology, has closed a Series A round of US$150 million financing.
Three investment companies, Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures, jointly invested in the round.
Founded in Shanghai and Suzhou, CStone’s pipeline covers five therapeutic areas, including oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases.
The funds raised will be used to accelerate CStone’s various programs into the clinical stage as well as develop new treatments for both local and international markets.
Source: WuXi Healthcare Ventures; Photo: Will Clayton/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.